<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04859725</url>
  </required_header>
  <id_info>
    <org_study_id>S63174</org_study_id>
    <nct_id>NCT04859725</nct_id>
  </id_info>
  <brief_title>HyperSpectral Imaging in Low Grade Glioma</brief_title>
  <acronym>HSI-LGG-2019</acronym>
  <official_title>Validation of Label-free, Wide-field, Real-time Intra-operative Tissue Discrimination and Tumor Detection of Low Grade Glioma Using a Hyperspectral Imaging (HSI) Sensor/Camera Integrated in the Operative Microscope</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Imec</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Carl Zeiss Meditec AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low grade glioma (LGG) is a slowly evolving, highly invasive intrinsic brain tumor displaying&#xD;
      only subtle tissue differences with the normal surrounding brain, hampering the attempts to&#xD;
      visually discriminate tumor from normal brain, especially at the border interface. This makes&#xD;
      anatomical borders hard to define during early maximal resection, which is the initial&#xD;
      treatment strategy. Therefore, innovative, robust and easy-to-use real-time strategies for&#xD;
      intra-operative detection and discrimination of (residual) LGG tumor tissue would strongly&#xD;
      influence on-site, surgical decision making, enabling a maximal extent of resection.&#xD;
&#xD;
      To validate this approach hyperspectral imaging (HSI) - using a SnapScan HSI-Camera (IMEC),&#xD;
      stably mounted on an OPMI Pentero 900 microscope (Zeiss) - will be used to generate spectral&#xD;
      imaging data patterns that discriminate in vivo low grade glioma tissue from normal brain&#xD;
      both on the cortical and subcortical level.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Included patients will undergo a resection of the low grade glioma as standard-of-care.&#xD;
      Before, during and after the resection, HSI data ('datacubes') will be acquired by the&#xD;
      SnapScan HSI camera on the microscope of all relevant areas of the exposed cortical surface&#xD;
      and subcortical cavity walls. The exact points of which the datacubes will be acquired are&#xD;
      defined by unequivocal single points on the neuronavigational system (Brainlab). From the&#xD;
      points from which the datacubes have been obtained a corresponding tissue sample will be&#xD;
      obtained (labeled biopsy) if tumor tissue is to be expected in that particular point, based&#xD;
      on the current standard of care assessments intraoperatively using white light illumination&#xD;
      on the microscope, intraoperative navigation and intraoperative ultrasound. As such, normally&#xD;
      looking brain in the resection cavity wall, will only be biopsied if tumor free margins&#xD;
      should be proven as part of the standard-of-care operative procedure (non-critically eloquent&#xD;
      brain regions). The objective of this all is to get an initial high quality in vivo dataset&#xD;
      to start exploring the potential of the technology.&#xD;
&#xD;
      The project will follow a 'stop and go' design: during the first 9 months, the initially&#xD;
      collected spectrally corrected datacubes will be analyzed using machine learning on coded&#xD;
      data sets. After this initial phase, an interim analysis will be made from the full list of&#xD;
      analyzed datacubes. If a reliable and robust discriminative signal can be detected in low&#xD;
      grade glioma tissue, segregating these signals from those in normal tissue (as defined&#xD;
      pathologically and/or radiologically), efficacy is demonstrated (proof of concept) and the&#xD;
      trial will go on for further collecting of samples in the following 26 months. Within the&#xD;
      expanded dataset, the different spectral data patterns will be translated into user's&#xD;
      friendly pattern codes for rapid real-time, on-site detection and interpretation through&#xD;
      development of dedicated software. If no reliable signal can be retrieved from low grade&#xD;
      glioma tissue in vivo during the surgery, further recruitment of patients will be stopped. At&#xD;
      that time, the investigators and partners will decide on whether or not relevant amendments&#xD;
      to the study will be proposed or not.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>During the first 9 months, the initially collected spectrally corrected datacubes will be analyzed using machine learning. After 9 months, an interim analysis will be made on the datacubes from this primary set with an estimated 10 participants.&#xD;
If a reliable and robust discriminative signal can be detected in low grade glioma tissue, segregating these signals from those in normal tissue, the trial will go on collecting samples for the following 26 months with an inclusion of 10 to 15 participant per year. Within the expanded dataset, the different spectral data patterns will be translated into user's friendly pattern codes for rapid real-time, on-site detection and interpretation through development of dedicated software.&#xD;
If no reliable signal can be retrieved from low grade glioma tissue in vivo during the surgery, further recruitment of patients will be stopped. At that time, a decision will be taken on whether or not relevant amendments to the study will be proposed.</intervention_model_description>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of hyperspectral image patterns of superficial and deep tumor tissue with patterns of normal brain</measure>
    <time_frame>During the surgical procedure</time_frame>
    <description>Assessment of discriminate power of HSI data between 468 and 780 nm between tumor and normal brain tissue by comparison of data acquired on imec VNIR HSI Snapscan camera and gold standard image segmentation of brain tissue.&#xD;
Image segmentation of white light images acquired on the Pentero 900 surgical microscope will be performed based on the assessment of the surgeon and on histopathological assessment of biopsies taken within the standard of care procedure. A co-registration of the segmented images and will be transferred to subsequently acquired HSI data and used to statistical assess whether HSI data can be used to discriminate the spectral signatures of healthy and tumorous tissue in vivo.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Low Grade Glioma of Brain</condition>
  <arm_group>
    <arm_group_label>Hyperspectral Imaging with Snapscan camera</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Included patients will undergo a resection of the low grade glioma as standard-of-care. Hyperspectral imaging data will be acquired by the SnapScan HSI camera mounted on the (standard) surgical microscope.&#xD;
As such, the surgical procedure does not deviate from the common, standard-of-care surgical procedures, apart from the acquisition of intraoperative scanning images using the SnapScan HSI camera on the microscope. The objective of this all is to get an initial high quality in vivo dataset to start exploring the potential of the technology.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hyperspectral Imaging with Snapscan camera</intervention_name>
    <description>Before, during and after the resection, HSI data ('datacubes') will be acquired by the SnapScan camera of all relevant areas of the exposed cortical surface and subcortical cavity walls. The exact points of which the datacubes will be acquired are defined by unequivocal single points on the routinely used neuronavigational system. From the points from which the datacubes have been obtained a corresponding tissue sample will be obtained (labeled biopsy) if tumor tissue is to be expected in that particular point, based on the current standard of care assessments intraoperatively using white light illumination on the microscope, intraoperative navigation and intraoperative ultrasound. As such, normally looking brain in the resection cavity wall, will only be biopsied if tumor free margins should be proven as part of the standard-of-care operative procedure (non-critically eloquent brain regions).</description>
    <arm_group_label>Hyperspectral Imaging with Snapscan camera</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18 years&#xD;
&#xD;
          -  Radiologically suspected low grade glioma (newly diagnosed or recurrent)&#xD;
&#xD;
          -  Scheduled for tumor resection at UZ Leuven&#xD;
&#xD;
          -  Signed informed consent document prior to resection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children with age &lt; 18 years&#xD;
&#xD;
          -  If final pathology reveals other pathological diagnosis than low grade glioma,&#xD;
             datacubes will not be included in the final analysis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven De Vleeschouwer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steven De Vleeschouwer, MD, PhD</last_name>
    <phone>+3216344290</phone>
    <email>neurochirurgie@uzleuven.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 2, 2021</study_first_submitted>
  <study_first_submitted_qc>April 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Steven De Vleeschouwer</investigator_full_name>
    <investigator_title>Member of Staff Neurosurgery, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Hyperspectral imaging</keyword>
  <keyword>Low grade glioma</keyword>
  <keyword>Tissue discrimination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

